Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Labelled Comp Radiopharm. 2018 Mar 12;61(9):727–738. doi: 10.1002/jlcr.3605

Figure 4.

Figure 4

PET readout gave true-positive results despite discordance with biopsy findings. An ER+/HER2- invasive ductal BC patient with confirmed negative pathology in the primary lesion A) but presented with HER2-PET positive disease 2 years after primary diagnosis B). Biopsy of the same site resulted an ambiguous IHC score (2+) C). MSK-IMPACT assay confirmed the foci as truepositive D). Arrows point to lesions. This research was originally published in JNM. Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016;57(10):1523–1528. ©1by the Society of Nuclear Medicine and Molecular Imaging, Inc.(reproduced with permission from Ref. 52)